Category Archives: NextBio

Apache Hadoop, Big Data, Hadoop, HBase, MapReduce, Medical, NextBio, Partnerships

NextBio, Intel Collaborate to Optimize Hadoop for Genomics Big Data

Image representing nextbio as depicted in Crun...

NextBio and Intel announced today a collaboration aimed at optimizing and stabilizing the Hadoop stack and advancing the use of Big Data technologies in genomics. As a part of this collaboration, the NextBio and Intel engineering teams will apply experience they have gained from NextBio’s use of Big Data technologies to the improvement of HDFS, Hadoop, and HBase. Any enhancements that NextBio engineers make to the Hadoop stack will be contributed to the open-source community. Intel will also showcase NextBio’s use of Big Data.

“NextBio is positioned at the intersection of Genomics and Big Data. Every day we deal with the three V’s (volume, variety, and velocity) associated with Big Data – We, our collaborators, and our users are adding large volumes of a variety of molecular data to NextBio at an increasing velocity,” said Dr. Satnam Alag, chief technology officer and vice president of engineering at NextBio. “Without the implementation of our algorithms in the MapReduce framework, operational expertise in HDFS, Hadoop, and HBase, and investments in building our secure cloud-based infrastructure, it would have been impossible for us to scale cost-effectively to handle this large-scale data.”

“Intel is firmly committed to the wide adoption and use of Big Data technologies such as HDFS, Hadoop, and HBase across all industries that need to analyze large amounts of data,” said Girish Juneja, CTO and General Manager, Big Data Software and Services, Intel. “Complex data requiring compute-intensive analysis needs not only Big Data open source, but a combination of hardware and software management optimizations to help deliver needed scale with a high return on investment. Intel is working closely with NextBio to deliver this showcase reference to the Big Data community and life science industry.”

“The use of Big Data technologies at NextBio enables researchers and clinicians to mine billions of data points in real-time to discover new biomarkers, clinically assess targets and drug profiles, optimally design clinical trials, and interpret patient molecular data,” Dr. Alag continued. “NextBio has invested significantly in the use of Big Data technologies to handle the tsunami of genomic data being generated and its expected exponential growth. As we further scale our infrastructure to handle this growing data resource, we are excited to work with Intel to make the Hadoop stack better and give back to the open-source community.”


Apache Hadoop, Big Data, Hadoop, HBase, HDFS, MapReduce, Medical, NextBio, Partnerships

NextBio, Intel Collaborate to Optimize Hadoop for Genomics Big Data

Image representing nextbio as depicted in Crun...

NextBio and Intel announced today a collaboration aimed at optimizing and stabilizing the Hadoop stack and advancing the use of Big Data technologies in genomics. As a part of this collaboration, the NextBio and Intel engineering teams will apply experience they have gained from NextBio’s use of Big Data technologies to the improvement of HDFS, Hadoop, and HBase. Any enhancements that NextBio engineers make to the Hadoop stack will be contributed to the open-source community. Intel will also showcase NextBio’s use of Big Data.

“NextBio is positioned at the intersection of Genomics and Big Data. Every day we deal with the three V’s (volume, variety, and velocity) associated with Big Data – We, our collaborators, and our users are adding large volumes of a variety of molecular data to NextBio at an increasing velocity,” said Dr. Satnam Alag, chief technology officer and vice president of engineering at NextBio. “Without the implementation of our algorithms in the MapReduce framework, operational expertise in HDFS, Hadoop, and HBase, and investments in building our secure cloud-based infrastructure, it would have been impossible for us to scale cost-effectively to handle this large-scale data.”

“Intel is firmly committed to the wide adoption and use of Big Data technologies such as HDFS, Hadoop, and HBase across all industries that need to analyze large amounts of data,” said Girish Juneja, CTO and General Manager, Big Data Software and Services, Intel. “Complex data requiring compute-intensive analysis needs not only Big Data open source, but a combination of hardware and software management optimizations to help deliver needed scale with a high return on investment. Intel is working closely with NextBio to deliver this showcase reference to the Big Data community and life science industry.”

“The use of Big Data technologies at NextBio enables researchers and clinicians to mine billions of data points in real-time to discover new biomarkers, clinically assess targets and drug profiles, optimally design clinical trials, and interpret patient molecular data,” Dr. Alag continued. “NextBio has invested significantly in the use of Big Data technologies to handle the tsunami of genomic data being generated and its expected exponential growth. As we further scale our infrastructure to handle this growing data resource, we are excited to work with Intel to make the Hadoop stack better and give back to the open-source community.”


Apache Hadoop, Big Data, Hadoop, HDFS, MapReduce, Medical, NextBio, Partnerships

NextBio, Intel Collaborate to Optimize Hadoop for Genomics Big Data

Image representing nextbio as depicted in Crun...

NextBio and Intel announced today a collaboration aimed at optimizing and stabilizing the Hadoop stack and advancing the use of Big Data technologies in genomics. As a part of this collaboration, the NextBio and Intel engineering teams will apply experience they have gained from NextBio’s use of Big Data technologies to the improvement of HDFS, Hadoop, and HBase. Any enhancements that NextBio engineers make to the Hadoop stack will be contributed to the open-source community. Intel will also showcase NextBio’s use of Big Data.

“NextBio is positioned at the intersection of Genomics and Big Data. Every day we deal with the three V’s (volume, variety, and velocity) associated with Big Data – We, our collaborators, and our users are adding large volumes of a variety of molecular data to NextBio at an increasing velocity,” said Dr. Satnam Alag, chief technology officer and vice president of engineering at NextBio. “Without the implementation of our algorithms in the MapReduce framework, operational expertise in HDFS, Hadoop, and HBase, and investments in building our secure cloud-based infrastructure, it would have been impossible for us to scale cost-effectively to handle this large-scale data.”

“Intel is firmly committed to the wide adoption and use of Big Data technologies such as HDFS, Hadoop, and HBase across all industries that need to analyze large amounts of data,” said Girish Juneja, CTO and General Manager, Big Data Software and Services, Intel. “Complex data requiring compute-intensive analysis needs not only Big Data open source, but a combination of hardware and software management optimizations to help deliver needed scale with a high return on investment. Intel is working closely with NextBio to deliver this showcase reference to the Big Data community and life science industry.”

“The use of Big Data technologies at NextBio enables researchers and clinicians to mine billions of data points in real-time to discover new biomarkers, clinically assess targets and drug profiles, optimally design clinical trials, and interpret patient molecular data,” Dr. Alag continued. “NextBio has invested significantly in the use of Big Data technologies to handle the tsunami of genomic data being generated and its expected exponential growth. As we further scale our infrastructure to handle this growing data resource, we are excited to work with Intel to make the Hadoop stack better and give back to the open-source community.”


Cancer Genome Atlas, Clinical trial, Medical, NextBio, Translational medicine

NextBio Clinical Extends Life Sciences Platform From the Bench to Translational Medicine

Image representing nextbio as depicted in Crun...

NextBio today unveiled NextBio Clinical, an extension of the company’s existing life sciences platform to translational medicine applications such as biomarker discovery and clinical trial optimization. Adding curated genomic, molecular and clinical profiles from thousands of individual patients to the platform’s existing repository of data from animal and cell line models, NextBio Clinical enables the earlier application of clinical information to enhance research and development.

“Since 2004, NextBio has been addressing the research needs of scientists at academic institutions, pharmaceutical and biotech companies with our cross-technology platform for integrative data analysis,” says Saeid Akhtari, NextBio President and Chief Executive Officer. “Now, with NextBio Clinical, we directly address the challenges of taking genomics into clinical research for the development of therapeutics and companion diagnostics. By providing patient-centric data and analysis, we facilitate biomarker-driven research that can accelerate the process of translational drug discovery.”

Mr. Akhtari concluded, “With the growing availability and decreasing cost of obtaining individual patient data moving genomics into clinical applications, NextBio Clinical is a natural extension for both our platform and our clients who have been using NextBio in their research for many years.”

NextBio Clinical aggregates and correlates terabyte-scale collections of private and public cross-platform ‘omics’ data, experimental data from cell lines and other sources, and clinical data from individual patients and population studies. Controlled vocabularies and the platform’s semantic framework eliminate confounding gene, disease and compound annotations, facilitating applications of this content at all stages of research, from early stage experimentation to repositioning approved drugs.

“With efforts such as The Cancer Genome Atlas, the International Cancer Genome Consortium and others, the growth of patient-level data in the public domain has been enormous. Simultaneously, efforts like the Cancer Cell Line Encyclopedia are transforming our understanding of pharmacogenomics with cell line models. We are excited about the potential of integrating these diverse data within the framework of NextBio Clinical,” said Ilya Kupershmidt, co-founder and Vice President of Products at NextBio.

Organizations can use the NextBio Clinical platform to accelerate drug discovery by applying human biology earlier in the discovery process, to discover and develop predictive biomarkers, and to optimize clinical trial design and patient selection to reduce development timelines and increase the chance of successful approval for new therapies.

Mr. Kupershmidt added, “By enabling our users to bring patient genomic data into the clinical development process at an early stage, we hope to help improve the pace and success rate at which biomarker-based therapeutics are approved for clinical use.”

Ilya Kupershmidt, Co-founder and VP of Products at NextBio, will describe NextBio Clinical in his talk at Bio-IT World 2012, titled “Patient-centered solutions for translational medicine” on Wednesday April 25, 2012 from 3:00-3:15 p.m. The meeting is being held in Boston, MA at the World Trade Center from April 24-26.

NextBio representatives are also available for additional information or product demos at Booth 326 in the exhibit hall.


Cancer Genome Atlas, Clinical trial, Medical, NextBio, Translational medicine

NextBio Clinical Extends Life Sciences Platform From the Bench to Translational Medicine

Image representing nextbio as depicted in Crun...

NextBio today unveiled NextBio Clinical, an extension of the company’s existing life sciences platform to translational medicine applications such as biomarker discovery and clinical trial optimization. Adding curated genomic, molecular and clinical profiles from thousands of individual patients to the platform’s existing repository of data from animal and cell line models, NextBio Clinical enables the earlier application of clinical information to enhance research and development.

“Since 2004, NextBio has been addressing the research needs of scientists at academic institutions, pharmaceutical and biotech companies with our cross-technology platform for integrative data analysis,” says Saeid Akhtari, NextBio President and Chief Executive Officer. “Now, with NextBio Clinical, we directly address the challenges of taking genomics into clinical research for the development of therapeutics and companion diagnostics. By providing patient-centric data and analysis, we facilitate biomarker-driven research that can accelerate the process of translational drug discovery.”

Mr. Akhtari concluded, “With the growing availability and decreasing cost of obtaining individual patient data moving genomics into clinical applications, NextBio Clinical is a natural extension for both our platform and our clients who have been using NextBio in their research for many years.”

NextBio Clinical aggregates and correlates terabyte-scale collections of private and public cross-platform ‘omics’ data, experimental data from cell lines and other sources, and clinical data from individual patients and population studies. Controlled vocabularies and the platform’s semantic framework eliminate confounding gene, disease and compound annotations, facilitating applications of this content at all stages of research, from early stage experimentation to repositioning approved drugs.

“With efforts such as The Cancer Genome Atlas, the International Cancer Genome Consortium and others, the growth of patient-level data in the public domain has been enormous. Simultaneously, efforts like the Cancer Cell Line Encyclopedia are transforming our understanding of pharmacogenomics with cell line models. We are excited about the potential of integrating these diverse data within the framework of NextBio Clinical,” said Ilya Kupershmidt, co-founder and Vice President of Products at NextBio.

Organizations can use the NextBio Clinical platform to accelerate drug discovery by applying human biology earlier in the discovery process, to discover and develop predictive biomarkers, and to optimize clinical trial design and patient selection to reduce development timelines and increase the chance of successful approval for new therapies.

Mr. Kupershmidt added, “By enabling our users to bring patient genomic data into the clinical development process at an early stage, we hope to help improve the pace and success rate at which biomarker-based therapeutics are approved for clinical use.”

Ilya Kupershmidt, Co-founder and VP of Products at NextBio, will describe NextBio Clinical in his talk at Bio-IT World 2012, titled “Patient-centered solutions for translational medicine” on Wednesday April 25, 2012 from 3:00-3:15 p.m. The meeting is being held in Boston, MA at the World Trade Center from April 24-26.

NextBio representatives are also available for additional information or product demos at Booth 326 in the exhibit hall.